Clinical trial NCT03176225: Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair
Official title: Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Diseases
Lead sponsor: LeMaitre Vascular
Sponsor class: INDUSTRY
First posted: 2017-06-05
Enrollment: 142
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

Detailed description: The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

There will be 144 subjects enrolled, including 72 subjects in the trial arm and 72 subjects in the control arm.

Eligibility criteria: Inclusion Criteria:

1. Man or woman aged below 6 years old
2. The expected lifetime of no less than 12 months
3. Patients with congenital heart disease in symptoms of ventricular septal defect, atrial septal defect and tetralogy of fallot who need the surgical repair.
4. Physical conditions and vital signs meet requirements for the surgery.
5. The subjects and/or their guardians sign the written Informed Consent Form.

Exclusion Criteria:

1. Patients with severe visceral diseases in liver, kidney, etc.
2. Patients have unstable vital signs and not suitable for the indications.
3. Patients with severe allergic history (especially allergic to bovine materials)
4. Patients with the past medical history of severe immunodeficiency disease
5. The subject has used or plans to use immunomodulatory drugs for more than half a year.
6. The subject with poor blood clotting function, which is defined as that pre-operative INR or APTT is prolonged over 30% than the reference value without drug intervention, or that blood platelet count is less than 100\*10\^9/L.
7. The subject has severe kidney disorders or diseases with the estimated glomerular filtration rate \[GRF\]\<30mL/min/1.73m2.
8. The subject's ALT or AST level is 2.5 times higher than the upper normal limit or the subject has active liver disease or icterus.
9. The subject has participated in another clinical study within past 3 months or is participating in another clinical study now.
10. The investigator believes that the subject has other reasons unsuitable for inclusion.

Primary outcomes:
measure: Leakage rate at 6 month post-procedure measured by ultrasound
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
Study officials:
References: